Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Simone RIBERO 1, 2, 3, Eugenio SPORTOLETTI BADUEL 1, Simona OSELLA-ABATE 4, Emi DIKA 5, Pietro QUAGLINO 2, Franco PICCIOTTO 1, Giuseppe MACRIPÒ 1, Veronique BATAILLE 3
1 Section of Dermatologic Surgery, Department of Oncology, Città della Salute e della Scienza di Torino Hospital, Turin, Italy; 2 Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy; 3 Department of Twins Research and Genetic Epidemiology, King’s College London, London, England; 4 Section of Surgical Pathology, Department of Medical Sciences, University of Turin, Turin, Italy; 5 Dermatology Department, University of Bologna, Bologna, Italy
The management of melanoma is constantly evolving. New therapies and surgical advances have changed the landscape over the last years. Since being introcuced by Dr Donald Morton, the role of sentinel lymph node has been debated. In many melanoma centres, sentinel node biopsy is not a standard of care for melanoma above 1 mm in thickness. The results of the MSLT-II trial are not available for a while and in the meantime, this procedure is offered as a prognostic indicator as it has been shown to be very useful for assessing risk of relapse. The biology of lymph node spread in melanoma is a complex field and there are many factors which influence it such as age, melanoma body site, thickness but other factors such as regression, ulceration and gender need further evaluation.